Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (OCS) notified investors on Feb 18, 2026 that certain managerial transactions relate to the vesting of earnout shares and the associated removal of restrictions on those ordinary shares.
The notifications name four managers: Anthony Rosenberg, Pall Johannesson, Riad Sherif, and Sylvia Cheung.
Oculis (Nasdaq: OCS) appointed Katie Kazem as Chief Legal Officer on Feb 17, 2026, to lead legal, compliance, and corporate governance functions.
Ms. Kazem brings 15+ years of capital markets and life‑sciences legal experience and has advised Oculis since its NASDAQ listing in March 2023. The move coincides with Privosegtor entering the PIONEER registrational program and DIAMOND Phase 3 topline results expected in Q2 2026.
Oculis (Nasdaq: OCS) said it will present its late-stage ophthalmology and neuro-ophthalmology pipeline at the 2026 J.P. Morgan Healthcare Conference on Jan 14, 2026.
The company highlighted Privosegtor, granted breakthrough therapy designation for optic neuritis after ACUITY Phase 2 showed a mean +18 ETDRS letters at three months versus placebo, and announced the global PIONEER registrational program (PIONEER-1 started in Q4 2025). Oculis also expects DIAMOND Phase 3 topline results for OCS-01 in DME in Q2 2026 and plans an NDA submission in Q4 2026.
Oculis (Nasdaq: OCS) announced the U.S. FDA granted Breakthrough Therapy Designation to Privosegtor for treatment of optic neuritis on January 6, 2026. The designation is supported by Phase 2 ACUITY data showing an average +18‑letter gain in Low Contrast Visual Acuity (LCVA) at month 3 versus IV steroid alone, plus anatomical preservation and reduced neurofilament release. Oculis launched the registrational PIONEER program after a 2025 FDA meeting; PIONEER includes three pivotal trials and PIONEER‑1 in optic neuritis was initiated in Q4 2025 with global site activation and enrollment expected to begin shortly. The company cites a U.S. market opportunity of $7 billion for key optic neuropathies.
Oculis (OCS) announced a notification relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The notice names Riad Sherif and is dated January 5, 2026; an attachment titled "Notification of managers' transaction - Riad Sherif - January 2026 RSU vest" is referenced.
The announcement reports the administrative event only and does not disclose amounts, prices, or additional financial details.
Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors. The notifications name four directors: Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, and indicate these RSUs vested/settled in December 2025.
These are routine managers' transaction disclosures concerning executive/director compensation events; no financial amounts or additional terms were included in the text provided.
Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando on October 16-20, 2025.
Key updates include the acceleration of Privosegtor into registrational trials after a positive FDA meeting, topline readouts from the Phase 3 DIAMOND program for OCS-01 in diabetic macular edema expected in Q2 2026, and the planned start of the genotype-based PREDICT-1 registrational trial for Licaminlimab anticipated in Q4 2025. Presenters include CEO Riad Sherif, MD and retina advisor Arshad M. Khanani, MD.
Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.
The notification identifies Arshad Khanani and records an RSU vest dated 29 November 2025.
Oculis (OTC:OCS) announced a notification of a managers' transaction relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a company director.
The notification names Arshad Khanani and cites an RSU vesting event dated 25 November 2025. No financial amounts or additional transactions were disclosed.
Oculis (Nasdaq: OCS) announced that a positive FDA meeting enables a registrational development program for Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company will launch the PIONEER program with three pivotal trials: PIONEER-1 (AON, expected Q4 2025), PIONEER-2 (AON, 1H 2026) and PIONEER-3 (NAION, mid-2026). Primary endpoint: low-contrast visual acuity at 3 months. Trials will mirror Phase 2 ACUITY dosing/enrollment. Oculis reported ≈$182 million cash and short-term investments as of Sept 30, 2025, with a cash runway into 2H 2027. Management will host an analyst call today at 8:30 AM ET.